Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Catalyst Pharm Inc 355 ALHAMBRA CIRCLE SUITE 1250 CORAL GABLES FL 33134 USA P: 305-420-3200 F: 305-529-0933


CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.

Key Statistics


Market Capitalization, $K 420,127
Shares Outstanding, K 102,470
Annual Sales, $ 0 K
Annual Net Income, $ -18,070 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,180 K
36-Month Beta 1.69
% of Insider Shareholders 9.60%
% of Institutional Shareholders 34.83%


1-Year Total Return 251.69%
3-Year Total Return 41.87%
5-Year Total Return 831.82%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -17.86%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/08/17
Earnings Per Share ttm -0.21
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

CPRX Ratios

Price/Earnings ttm 0.00
Price/Earnings forward -19.07
Price/Earnings to Growth N/A
Return on Equity % -48.86
Return on Assets % -45.62
Net Margin % N/A
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 11.06
Book Value/Share 0.38
Interest Coverage 0.00
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.